Home
About
Overview
Sharing Data
ORCID
Help
History (5)
Attention to Immortal Time Bias in Critical Care Research.
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500?mg/m(2) every 21 days in patients with cancer.
PTEN loss in the Myf5 lineage redistributes body fat and reveals subsets of white adipocytes that arise from Myf5 precursors.
RNA Processing, Post-Transcriptional
Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.
See All 5 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Attention to Immortal Time Bias in Critical Care Research.
Vail EA, Gershengorn HB, Wunsch H, Walkey AJ. Attention to Immortal Time Bias in Critical Care Research. Am J Respir Crit Care Med. 2021 05 15; 203(10):1222-1229.
View in:
PubMed
subject areas
Bias
Critical Care
Health Services Research
Humans
Research Design
Time Factors
authors with profiles
Allan Jay Walkey MD, MSc